The United States would save $1.3 billion annually if FDA were to approve seven complex generics already available in Canada or Europe, according to report by US Matrix Global Advisors. Congress must renew FDA’s generic user fee program next year, and that is viewed as the vehicle for speeding complex generic drug approvals. Complex generics copy brand drugs with complex molecular bases, routes of delivery, formulations or dosage forms They can be drug-device combination product, such as generic versions of...